MedTrace Logo

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

NCT00393380 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2013-04-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to successfully begin producing new blood cells.

Conditions

  • Leukemia, Myeloid, Chronic
  • Anemia, Aplastic
  • Myelofibrosis
  • Lymphoma
  • Hodgkin Disease
  • Leukemia, Lymphocytic, Chronic
  • Leukemia, Myelocytic, Acute
  • Leukemia, Lymphocytic, Acute

Interventions

DRUG

Parathyroid Hormone (teriparatide)

Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC\>2000/microL: PTH 100 mcg

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • The Emmes Company, LLC

    lead INDUSTRY

Principal Investigators

  • Karen K. Ballen, MD · Massachusetts General Hospital

  • Joseph Antin, MD · Dana-Farber Cancer Institute

  • David Avigan, MD · Beth Israel Deaconess Medical Center

  • Elizabeth J Shpall, MD · MD Anderson Cancer Research Center

  • Colleen Delaney, MD · Fred Hutchinson Cancer Center

  • Ram Kamble, MD · Baylor College of Medicine

  • Katarzyna Jamieson, M.D. · University of Florida

  • Philip McCarthy, M.D. · Roswell Park Cancer Institute

  • Edward Ball, M.D. · University of California, San Diego

  • Richard Maziarz, M.D. · Oregon Health and Science University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-11-30
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00393380 on ClinicalTrials.gov